3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Turcot syndrome
1
Pancreatic Neoplasms
1
Oligoprogressive
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Breast Cancer Patients
1
Interventions
Nivolumab
5
pembrolizumab
3
avelumab
3
Neoadjuvant Therapy
3
toripalimab
2
durvalumab
2
atezolizumab
2
Celecoxib
2
spartalizumab
1
relatlimab
1
fludarabine phosphate
1
fludarabine
1
dostarlimab
1
danvatirsen
1
XELOX
1
Surgical Procedures, Operative
1
Oxaliplatin
1
Leucovorin
1
Ipilimumab
1
Induction Chemotherapy
1
Immunotherapy
1
Immunoglobulin G
1
Immune Checkpoint Inhibitors
1
IMM-101
1
Fluorouracil
1
Docetaxel
1
Disulfides
1
DEAE-Dextran
1
Cyclophosphamide
1
Chemotherapy, Adjuvant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Turcot syndrome
×
DEAE-Dextran
×
Clear all
NCT07403877
2026-02-11
TORCH-OPTIMA
Fudan University
Phase 2
Not yet recruiting
114 enrolled